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Background: Genetic predisposition of the inﬂammatory-host response may affect the development of
psoriasis. Previous studies have shown that copy number variations (CNVs) of b-defensin genes (DEFB)
are associated with the susceptibility of psoriasis in Caucasian populations.
Objectives: This study aimed to assess the role of the CNVs of the DEFB4 gene and functional variants in
the DEFB1 gene in Taiwanese patients with psoriasis.
Methods: In total, 196 patients with psoriasis and 196 control individuals were analyzed for the presence
of the DEFB4 CNVs using the paralogue ratio test, and also for the DEFB1 polymorphisms rs11362,
rs1800972, and rs1799946, using a polymerase chain reaction.
Results: None of the polymorphisms were found to be associated with psoriasis. The distribution of
DEFB4 genomic CNVs did not signiﬁcantly differ between the control group and psoriasis group. The
frequencies of patients who carried a greater than the median ( 5) number of copies did not signiﬁ-
cantly differ in patients with psoriasis and controls. The multivariate analysis similarly revealed that the
DEFB4 CNVs were not associated with psoriasis (odds ratio ¼ 1.03, 95% conﬁdence interval ¼ 0.89e1.19,
p ¼ 0.720). No signiﬁcant difference was detected in the genotype and allele distribution for any of the
individual DEFB1 polymorphisms between the cases and the controls. Finally, the overall haplotype
frequency proﬁles derived from the three polymorphisms did not signiﬁcantly differ between the cases
and the controls.
Conclusion: Our results do not suggest that these genetic variants of the b-defensin genes contribute to
the genetic background of psoriasis in Taiwanese patients.
Copyright © 2015, Taiwanese Dermatological Association.
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Psoriatic skin lesions are characterized by histological evidence of
inﬂammation, abnormal keratinocyte proliferation/terminal dif-
ferentiation, and dermal angiogenesis.1 Although the etiology of
psoriasis remains unknown, it is clear that an interaction among
genetic susceptibility variants, the immune system, and environ-
mental factors contribute to the development of the chronic in-
ﬂammatory process.2
Human b-defensins (hBDs) are a family of small, secreted anti-
microbial peptides. In addition to antibacterial and antiviral effects,er Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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reactions that protect the host from various pathogens.3 The
expression of hBD-1 is generally constitutive, and the level of hBD-2
is thought to be induced by proinﬂammatory cytokines and bac-
teria.4 Histologically, hBDs are expressed by epithelial cells of the
skin, gut, respiratory tissue, and urogenital tissue.5,6 In addition to
epithelial cells, the expression of hBD-1 and hBD-2 have also been
found in human monocytes, macrophages, and dendritic cells
(DCs).7
HBDs are encoded by DEFB genes in three main gene clusters:
two on chromosome 20 and one on chromosome 8p23.1. Of the
eight b-defensin genes at 8p23.1, not including DEFB1 (encoding
the protein hBD-1) but including DEFB4 (encoding the protein
hBD-2), SPAG11, DEFB103 (encoding the protein hBD-3), DEFB104
(encoding the protein hBD-4), DEFB105, DEFB106, and DEFB107, are
on a large repeat unit that varies in copy number. In humans, up to
12 copies of this repeat have been found, and three to ﬁve copies
per diploid genome are more prevalent.8 HBD-2, hBD-3, and hBD-4
have been demonstrated to stimulate keratinocytes to release
interleukin (IL) IL-8, IL-18, and IL-20, which are all proin-
ﬂammatory cytokines that have an established role in the patho-
genesis of psoriasis.9 Recently, Hollox et al10 found an association
between higher copy number variations (CNVs) for DEFBs on
chromosome 8p23.1 and risk of psoriasis in a Caucasian popula-
tion. However, the relationship of DEFBs CNVs and psoriasis, until
now, remains unclear in the Chinese population. Further, the role
of the DEFB1 gene as a potential modiﬁer in psoriasis has not
previously been studied. Three singe nucleotide polymorphisms
(SNPs) at positions c.-20G>A (rs11362), c.-44C>G (rs1800972), and
c.-52G>A (rs1799946) in the 5'-untranslated region of DEFB1 gene
have been described to inﬂuence the hBD-1 expression or func-
tion.11,12 Recent studies in the Mexican, Egyptian, and Korean
populations have identiﬁed an association between DEFB1 SNPs
and the susceptibility of atopic dermatitis,13e15 which shares with
psoriasis the similar phenotypes of dry, scaly skin and disturbed
epidermal differentiation. We, therefore, consider it to be impor-
tant to investigate the relevance of the SNPs of the DEFB1 gene and
the CNVs of the DEB4 genes in patients with psoriasis among the
Taiwanese population.Methods
Study population
One hundred and ninety-six patients with chronic plaque psoriasis
and 196 control participants, comparable for age and gender, were
enrolled in this study. Patients with psoriasis were diagnosed by
means of clinical and/or histopathological ﬁndings. Severity of
psoriasis was categorized into three divisions based on the area on
the body affected by psoriasis: (1) affected surface of < 5% was
categorized as mild psoriasis; (2) 5e10% affected area was moder-
ate psoriasis; and (3) > 10% affected area was severe psoriasis. Pa-
tients whose disease onset was younger than 40 years were
considered to have “early onset” psoriasis, and those whose disease
onset was older than 40 years were diagnosed as “late onset”.
Control participants responded to a questionnaire on their medical
history and lifestyle characteristics, and they were recruited during
routine health examinations from which no clinical evidence of
psoriasis was found by the research nurses. The study protocol was
approved by the hospital's ethics committee (Chang Gung Medical
Foundation Institutional Review Board (Taipei, Taiwan; 100-
4528A3 and 103-7245C), and conducted in accordance with the
principles of the Declaration of Helsinki. Written informed consent
was obtained from all participants.Genomic DNA extraction
Genomic DNA of patients and controls was respectively isolated
from oral epithelial cells and peripheral blood leukocytes, with the
standard method using proteinase K digestion of the nuclei.
Paralogue ratio test-based restriction enzyme digest variant
ratio
A paralogue ratio test (PRT) was performed, as previously re-
ported,16 using the HSPDP3 system (a heat-shock protein pseudo-
gene of ~2 kb), which speciﬁcally ampliﬁed chromosome 8 (DEFB4)
in conjunction with reference products from chromosome 5, with
products differing by 4 bp. The primers were HSPD5.8F (CCA-
GATGAGACCAGTGTCC) and FAM-labelled HSPD5.8R (TTTTAAGTT-
CAGCAATTACAGC). Genomic DNA of 5 ng was ampliﬁed in a ﬁnal
volume of 20 mL, with 0.5mM forward primer and 0.5mM FAM-
labelled reverse primer, in a buffer containing ﬁnal concentra-
tions of 50mM Trisehydrochloride (pH 8.8), 12mM ammonium
sulfate, 5mM magnesium chloride, 125 mg/mL bovine serum albu-
min (non-acetylated, Ambion Inc., Austin, TX, USA), 7.4mM 2-
mercaptoethanol, and 1.1mM each deoxynucleotide (sodium
salts), with 0.5U Taq DNA polymerase in a total volume of 10 mL.
Products were ampliﬁed using 30 cycles of 95C for 30 seconds,
53C for 30 seconds, and 70C for 30 seconds, followed by a single
“chase” phase of 53C for 1min/70C for 20minutes. One mL of each
polymerase chain reaction product was added to a 10 mL digestion
containing 1 ReAct 2 buffer [50mM Tris-hydrochloride (pH 8.0),
10mMMgCl2, and 50mM NaCl] (Invitrogen, CA, USA) and 5U HaeIII
(New England Biolabs, MA, USA). After incubation at 37C for 4e16
hours, 2 mL was added to 10 mL HiDi formamide with ROX-500
marker (Applied Biosystems, Warrington, UK), and analyzed using
electrophoresis on an ABI3100 (Applied Biosystems, Foster City, CA)
36 cm capillary using the POP4 polymer. The test (chromosome 8
DEFB4) and reference (chromosome 5) amplicons were distin-
guished by using the GeneScan Analysis software (PE Applied
Biosystems, Foster City, CA).
Genotyping of DEFB1 -20G>A (rs11362), -44C>G (rs1800972),
and -52G>A (rs1799946) polymorphisms
To determine the genotype of the rs11362 polymorphism, poly-
merase chain reaction ampliﬁcationwas performed using a forward
primer 50-CAGGGGTTAGCGATTAG-30, and a reverse primer 50-
GCAGAGAGTAAACAGAAGGTA-30. An ampliﬁed product of 227 bp
was digested with BstNI, with resulting fragments of 167 bp for the
GG wild type, 227 bp for the AA homozygote, and 167 bp and
227 bp for the GA heterozygote. Genotyping for the SNP rs1800972
and rs1799946 were performed using TaqMan SNP Genotyping
Assays obtained from Applied Biosystems (ABI, Foster City, CA,
USA).
Statistical analyses
The clinical characteristics of continuous variables were expressed
as mean ± standard deviation, and were tested using a two-sample
t test. Either the Chi-square test or Fisher's exact test was used to
examine the differences in categorical variables and to compare the
allele and genotype frequencies. The KolmogoroveSmirnov test
was used to compare the shape of the CNVs frequency distribu-
tions. Binary logistic regression analysis was used to evaluate the
independent effect of investigated genotypes on the risk of psori-
asis, adjusted for age, gender, smoking, diabetes, hypertension, and
body mass index (BMI). The analysis of deviation from the Har-
dyeWeinberg equilibrium, estimation of the linkage disequilibrium
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formed using SNPStats software (available at http://bioinfo.
iconcologia.net/SNPstats).Figure 1 Frequency distribution of the DEFB4 copy numbers in controls (n ¼ 196) and
psoriasis patients (n ¼ 196).Results
Table 1 lists the characteristics of the cases and control participants.
There was no signiﬁcant difference between the two groups with
regard to gender, age, hypertension, diabetes, smoking, and BMI.
The distributions of the DEFB4 genomic copy number in the study
population, shown in Figure 1, exhibited a range of 2e11 per
genome, with a median number of ﬁve copies. The difference in
overall DEFB4 genomic copy number distribution between psoriasis
patients and control participants was insigniﬁcant, as determined
with the KolmogoroveSmirnov test (p ¼ 0.657). The proportions of
control individuals who carried a number of copies less than the
median (< 5) or greater than median ( 5) were 42.9% and 57.1%,
respectively. In the patients with psoriasis, the frequency of dis-
tribution of the subgroup (38.8% and 61.2%) did not signiﬁcantly
differ from that of the control group (p ¼ 0.411; Figure 2). In-
dividuals with a copy number 5 had an insigniﬁcantly higher risk
of psoriasis than did individuals with a copy number < 5 (odds
ratio ¼ 1.18, 95% conﬁdence interval ¼ 0.79e1.77). The average
number of copies per genome in psoriasis patients was slightly
greater than that of the control participants (5.14 ± 2.01 vs.
5.02 ± 1.75), but the difference did not reach statistical signiﬁcance
(p ¼ 0.520). In the logistic regression analysis with the DEFB4 CNVs
as an integer variable, they were also not associated with psoriasis
after adjusting for age, sex, smoking, diabetes, hypertension, and
BMI (odds ratio ¼ 1.03, 95% conﬁdence interval ¼ 0.89e1.19,
p¼ 0.720). Additionally, comparison between the disease subgroup
(i.e., early/late onset and severity of psoriasis) among psoriasis
patients, revealed no signiﬁcant difference in the frequencies of the
carriers with a copy number  5 (data not shown).
The genotype and allele frequencies of the DFEB1 20G>A
(rs11362), 44C>G (rs1800972), and 52G>A (rs1799946) poly-
morphisms in psoriasis patients and controls are presented in
Table 2. Some of the study participants could not be genotyped for
the polymorphisms because their DNA samples had been used up
for other studies. No signiﬁcant deviation from the HardyeWein-
berg equilibrium was detected for the DFEB1 SNPs in either the
study cases or the controls. All SNPs were in strong pairwise linkage
disequilibrium. As can be seen in Table 2, none of the poly-
morphisms were found to be associated with psoriasis. No signiﬁ-
cant difference was observed in genotype and allele distribution for
any of the DEFB1 polymorphisms between the cases and the con-
trols. After adjustment for age, sex, smoking, diabetes, hyperten-
sion, and BMI, the results remained unchanged (data not shown).
Additionally, the overall haplotype frequency proﬁles did not differ
signiﬁcantly between the psoriasis cases and the controls (Table 3;
p ¼ 0.77). Furthermore, comparison between the disease subgroupTable 1 Clinical characteristics of the psoriatic patients and controls.
Controls Patients p
No. 196 196
Age (y) 48 ± 11 49 ± 16 0.295a
Men/women 152/44 154/42 0.807b
Smoking (%) 32.7 25.0 0.094b
Diabetes mellitus (%) 3.1 7.1 0.066b
Hypertension (%) 15.82 19.4 0.353b
Body mass index (kg/m2)c 25.2 ± 3.4 25.3 ± 4.7 0.821a
a By two-sample t test
b By c2 test
c Ninety-eight psoriasis patients had missing data on body mass index status.(i.e., early/late onset and severity of psoriasis) among psoriasis
patients, revealed no signiﬁcant difference in the frequencies of the
DEFB1 alleles and genotypes (data not shown).Discussion
In the present caseecontrol study, we found no evidence of an
association between SNPs rs11362, rs1800972, and rs1799946 in
the DEFB1 gene and the risk of psoriasis. There were also no re-
lationships between the DEFB4 CNVs and the risk of psoriasis. Our
results therefore suggest that these polymorphisms are not
important risk factors for psoriasis among Chinese living in Taiwan.
b-defensins are antimicrobial peptides that are also proin-
ﬂammatory because they act as chemokines for immune cells, such
as T cells and DCs.17 Hollox et al10 ﬁrst reported the association
between the risk of psoriasis and increased b-defensin genomic
copy number. Individuals with a copy number > 5 are about ﬁve
times more likely to have psoriasis than individuals with a copy
number of 2, and there is a signiﬁcant linear increase in relative risk
with increasing copy number (odds ratio around 1.32). This asso-
ciation was replicated in a subsequent study with three cohorts of
European origin, although with a reduced odds ratio of 1.081.18 A
previous study showed a positive relationship between b-defensin
copy number and mucosal hBD-2 mRNA expression in patients
with colon Crohn disease.19 Recently, Jansen et al20 have further
demonstrated a signiﬁcant correlation between serum hBD-2 levels
and b-defensin copy number in healthy individuals. Moreover,
hBD-2 is strongly expressed in lesional psoriatic epidermis and
high systemic hBD-2 levels are strongly correlated with diseaseFigure 2 Distribution of the DEFB4 copy numbers in controls (open bars) and psoriasis
patients (gray bars) allocated to < 5, or  5 copies per genome. The p value ¼ 0.411
(using c2 test) for the controls versus psoriatic patients.
Table 2 Allele and genotype frequencies of the single nucleotide polymorphisms rs11362, rs1800972, and rs1799946 in the DEFB1 gene in the study population.
Genotype pa Allele pa
rs11362 GG GA AA G A
Controls (n ¼ 184) 72 (39.1) 82 (44.6) 30 (16.3) 0.609 0.614 0.386 0.818
Psoriasis (n ¼ 188) 71 (37.8) 92 (48.9) 25 (13.3) 0.622 0.378
rs1800972 CC CG GG C G
Controls (n ¼ 187) 147 (78.6) 36 (19.3) 4 (2.1) 0.061 0.882 0.118 0.784
Psoriasis (n ¼ 171) 133 (77.8) 38 (22.2) 0 (0) 0.889 0.111
rs1799946 GG GA AA G A
Controls (n ¼ 190) 54 (28.4) 83 (43.7) 53 (27.9) 0.075 0.503 0.497 0.772
Psoriasis (n ¼ 190) 41 (21.6) 105 (55.3) 44 (23.2) 0.492 0.508
Data are presented as n (%).
a Two-sided c2 test for distributions of either genotype or allele frequencies between the cases and controls.
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Therefore, it is hypothesized that an inappropriately high amount
of hBD-2 leads to an inappropriate inﬂammatory response, thereby
triggering a psoriatic plaque. However, we could not replicate this
association in a Chinese population living in Taiwan, although the
average number of copies per genome in psoriasis patients was
slightly greater than that of control participants. The differences
may be due to ethnic variation in diplotype frequency distributions
or environmental inﬂuences. Accurate copy number typing of the
b-defensin CNV region has been challenging, and only the PRT
method was used in this study. However, the PRT method has been
shown to provide a high degree of concordance with other
methods, including multiplex ampliﬁable probe hybridization,
multiple ligation probe ampliﬁcation, and array-comparative
genomic hybridization.16 Our data, which accords with previous
ﬁndings, revealed that the distributions of Chinese populations
shifted slightly toward higher copy numbers compared with Eu-
ropean populations.21 Another possible reason to explain the
apparent genetic difference of our ﬁndings is the small sample size
for our study. A sample size of nearly 10,000 cases and controls is
required to detect such a small genetic effect with 80% statistical
power.
To the best of our knowledge, this is the ﬁrst investigation
regarding the effect of the DEFB1 polymorphisms on the risk of
psoriasis. Previous studies have found an association between the
DEFB1 SNPs and the susceptibility of atopic dermatitis in different
ethnic populations.13e15 It has been reported that the rs11362,
rs1800972, and rs1799946 in the 50- untranslated region of the
DEFB1 gene may cause functional variations in the expression of
hBD-111,12 and are associated with autoimmune diseases like sys-
temic lupus erythematosus.22 However, our study was unable to
demonstrate an association between psoriasis and genetic variants
of DEFB1. HBD-1 mRNA and peptide were found to be expressed
consistently in the skin samples from various body sites and
localized to the suprabasal keratinocytes, sweat ducts, and seba-
ceous glands of human skin.23 Both hBD-1 and hBD-2 exhibit
chemotactic activity for cells stably transfected with CC chemokine
receptor 6 (CCR6). HBD-1 may function through interaction withTable 3 Frequencies of the common haplotypes derived from the single nucleotide
polymorphisms rs11362, rs1800972, and rs1799946 in the DEFB1 gene in
the study population.
rs11362 rs1800972 rs1799946 Total* Controls Psoriasis
H1a G C A 0.4883 0.4784 0.4989
H2 A C G 0.371 0.3741 0.3679
H3 G G G 0.108 0.1108 0.1050
H4 G C G 0.0185 0.0172 0.0198
H5 A C A 0.0097 0.0110 0.0084
* p ¼ 0.77.
a Likelihood ratio test for global haplotype effect.CCR6 to recruit immature DCs and memory T cells to cutaneous
sites of microbial invasion.17 CCR6 was found to be required for IL-
23-induced psoriasis-like inﬂammation in mice,24 and is consid-
ered to be a therapeutic target in psoriasis.25,26 However, gene
expression of hBD-1 in keratinocytes, in contrast to hBD-2, is not
subject to regulation by proinﬂammatory cytokines,27 as it is not
highly induced in psoriatic skin.20 In addition, enhanced proin-
ﬂammatory cytokines expression by keratinocytes is associated
with the stimulation by hBD-2 but not hBD-1.9 Taken together, our
research suggests that DEFB1may not play an important role in the
development of psoriasis.
Our study has several limitations. Firstly, because the sample
size of our study is relatively small, we cannot on the basis of our
results exclude the possibility of a relatively small risk of psoriasis
associated with the studied CNVs and SNPs. Secondly, we did not
assess the effect of the DEFBs variants on the local hBD-1 and hBD-2
expressions in psoriatic plaques. Moreover, our study has a cross-
sectional design and provides no information about the effect of
the DEFB variants on the progression of psoriasis or its clinical
outcome. A larger prospective and longitudinal study would be
necessary to fully assess the signiﬁcance of these polymorphisms in
psoriasis. Moreover, the examined patients were ethnically Chi-
nese, and caution should be exercised when extrapolating our re-
sults to other ethnic groups.
In conclusion, our study results do not support the associations
of susceptibility with psoriasis among Taiwanese with the
DEFB1 20G>A, 44C>G, 52G>A SNPs, and DEFB4 CNVs.
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